Quantcast
The Name Of A Drug Significantly Influences How The Patient

The Name Of A Drug Significantly Influences How The Patient Feels About The Treatment

Rayshell Clapper for redOrbit.com - Your Universe Online Many individuals rely on pharmacology for different physical or mental health issues. However, some conditions require certain pharmacology which can be described as used for something...

Latest Organofluorides Stories

2014-10-30 16:25:23

OTTAWA, Oct. 30, 2014 /CNW Telbec/ - Health Canada today released the October 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue includes an article on diabetes drugs known as incretin-based therapies and a possible association with pancreatic cancer. It also includes an article on the potential risk of liver injury associated with a steroid drug called methylprednisolone when it is injected intravenously (into a vein). As well, it includes an article on...

2014-10-29 12:27:14

Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo...

2014-10-28 23:05:05

Micronized PTFE market report provides a comprehensive review of major market drivers, restraints, opportunities, winning imperatives, challenges, and key issues in the market.(http://www.marketsandmarkets.com/Market-Reports/micronized-ptfe-market-75866552.html) (PRWEB) October 28, 2014 The new research report, “Micronized PTFE Market by Application (Inks, Thermoplastics, Coatings, Grease & Lubricants, Elastomers), by Geography - Global Forecast to 2019”, defines and segments the...

2014-10-24 12:27:03

NEW YORK, Oct. 24, 2014 /PRNewswire/ -- As Risperdal lawsuits (www.risperdallawsuit2014.com) involving gynecomastia, or male breast growth, continue to move forward in U.S. courts, Bernstein Liebhard LLP notes the publication of new research linking the use of risperidone to the development of the condition. The findings, which appear in the October 2014 issue of the Journal of Clinical Psychopharmacology, were drawn from a comparison of 8,000 men who suffered from gynecomastia, ages...

2014-10-22 08:30:21

DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports for United States (US), China and Japan to the cancer drugs market research collection of its online library. The PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...

2014-10-21 12:22:28

MORRIS TOWNSHIP, N.J., Oct. 21, 2014 /PRNewswire/ -- The allegations outlined in the Statement of Objections are baseless and conflict with the EU's own laws that encourage collaboration on development. Honeywell is confident that our practices are consistent with the law and that the Commission will conclude that we acted in full compliance with European Union competition rules. By collaborating on expensive and risky development, Honeywell and DuPont were able to develop HFO-1234yf...

2014-10-21 12:21:08

WILMINGTON, Del., Oct. 21, 2014 /PRNewswire/ -- Thierry F.J. Vanlancker, president, DuPont Chemicals & Fluoroproducts, said the following about the European Commission's Statement of Objections: "DuPont has complied at all times with applicable laws in its development and commercialization of HFO-1234yf, and we plan to defend vigorously against the Commission's allegations and preliminary conclusions. This is one step in a long process, and while it may take years to be resolved,...

2014-10-20 12:24:41

Company Expects New Family of Products will Reduce Greenhouse Gas Content of Refrigerants by 245 Million Tons CO2 Equivalent Worldwide by 2025 WILMINGTON, Del., Oct. 20, 2014 /PRNewswire/ -- DuPont Fluorochemicals (DuPont) today announced the introduction of three new refrigerants in its more sustainable DuPont(TM) Opteon® family. These refrigerants have far lower global warming potential (GWP) than the products they are designed to replace and will enable compliance with a growing...

2014-10-18 23:01:41

The Firm is representing numerous Risperdal lawsuit plaintiffs in claims that allege the atypical antipsychotic medication caused gynecomastia, or male breast growth. New York, New York (PRWEB) October 18, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, 888 product liability claims have been filed in...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.